Drug intelligence / Profile preview

T2026

Development stage: Unknown
Lead developer: Sciwind Biosciences
Administration: Oral

Overview

T2026 is an investigational absorption enhancer being developed by Sciwind Biosciences. Its precise mechanism of action is currently unknown, and it does not represent a novel mechanistic class. T2026 has been studied in clinical trials as an adjunct to improve the absorption of orally administered drugs, such as ecnoglutide tablets for metabolic diseases like type 2 diabetes mellitus and obesity. As of now, there are no approved indications or known adverse events associated with T2026[1][7].

Beyond the preview

Go deeper on T2026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T2026.

Explore the full profile